

There's a life behind every test

Simple **RSV** testing for those at highest risk

The portable, easy-to-use **BD Veritor™ Plus System** provides reliable RSV results in 10 minutes.



*EUA Authorized by FDA



Be prepared for respiratory illness

RSV

When your pediatric patients[†] are in need of fast, reliable RSV testing, turn to the **BD Veritor™ Plus System**. Offering reliable results at point of care in a simple-to-operate, handheld instrument.



Simplifies the testing process

- Easy operation and single-button functionality may help reduce potential manual errors
- Provides intuitive sample processing with prefilled, unitized tubes



Delivers workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
 - » **Walk Away:** the test device is inserted into the Analyzer immediately after preparation, allowing staff to multitask while the sample incubates
 - » **Analyze Now:** the test device is inserted after the incubation time is complete, allowing batches of samples to be tested at once
- Option to test the same sample with a BD Veritor™ Flu A+B test device.¹



Achieves reliable, rapid results

- Displays easy-to-read digital results for RSV in 10 minutes¹
- Provides clear, objective results by correcting for nonspecific binding and detecting positives not recognized by the unaided eye¹



Provides result traceability

- Downloadable test records matched to kit lot number, operator, patient or specimen ID with the BD Veritor™ InfoWiFi module or via the companion ImageMover application
- Offers result printing capabilities via USB port

¹The BD Veritor™ RSV CLIA-waived kit is indicated for use in patients under 6 years of age. The BD Veritor™ RSV moderately complex kit is individual for use in patients under 20 years of age.

Reference: 1. BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV), package insert, 8086098. Franklin Lakes, NJ: Becton, Dickinson and Company

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA
800-638-8663

BDVeritor.com

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. (BD-43407 2039-US-0323 March 2023)

Offers proven performance (CLIA-waived kit)

	PPA [†]	NPA [‡]	Results in
Compared to viral culture	91.8% (95% CI: 85.9%, 95.4%)	93.3% (95% CI: 90.4%, 94.4%)	10
Compared to PCR	81.6% (95% CI: 75.2%, 86.6%)	99.1% (95% CI: 97.5%, 99.7%)	10

[†]positive percent agreement
[‡]negative percent agreement

Ordering information	Cat no.	Qty
BD Veritor™ Plus System RSV CLIA-waived kit	256038	30 tests
BD Veritor™ Plus System RSV moderately complex kit	256042	30 tests
BD Veritor™ Plus Analyzer	256066	1 unit

*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

